AstraZeneca (AZN) says “positive” results from the pivotal TROPION-Breast01 Phase III trial showed that datopotamab deruxtecan, or Dato-DXd, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, or PFS, compared to investigator’s choice of chemotherapy in patients with inoperable or metastatic hormone receptor-positive, HER2-low or negative breast cancer previously treated with endocrine-based therapy and at least one systemic therapy. These data will be shared today in the first of two late-breaking presentations for datopotamab deruxtecan in a Presidential Symposium at the European Society for Medical Oncology, or ESMO, 2023 Congress in Madrid, Spain. Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate, or ADC, being jointly developed by AstraZeneca and Daiichi Sankyo (DSNKY).
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo’s Enhertu approved in EU for certain NSCLC
- Updated results from BEGONIA Phase Ib/II trial presented at ESMO
- Results from primary analysis of the DUO-E Phase III trial presented at ESMO
- AstraZeneca’s TAGRISSO plus chemotherapy results presented at ESMO
- AstraZeneca reports ‘positive’ results from interim analysis of MATTERHORN trial
